Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00465075 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00465075 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 24 participants.
The verdict
NCT00465075, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The primary objective is to determine the effect of a high-fat meal on the bioavailability and PK of a single, oral dose of BZA/CE (PNP) 20mg/0.625 strength tablet, assessing both the BZA and CE components.
Interventions
- DRUG Bazedoxifene/conjugated estrogens combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00465075
The ClinicalTrials.gov registry entry for NCT00465075 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bazedoxifene/conjugated estrogens combination is the first listed.
NCT00465075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00465075 about?
NCT00465075 is a clinical study titled "Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women". The primary objective is to determine the effect of a high-fat meal on the bioavailability and PK of a single, oral dose of BZA/CE (PNP) 20mg/0.625 strength tablet, assessing both the BZA and CE components.
What is the current status of trial NCT00465075?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2007-03. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00465075?
The interventions under investigation include: Bazedoxifene/conjugated estrogens combination (DRUG).
Who is sponsoring clinical trial NCT00465075?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.